In a recent study, only one-third of the cancer trials that were the basis of FDA approvals in 2016 were found to demonstrate a “substantial clinical benefit” according to the European Society of Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).  Under the terms of this scale, for a drug to be considered to have a substantial clinical benefit, it not only has to be efficacious, but also has to include information on patient quality of life and postmarketing data. (Cancer Therapy Advisor)